Bruce Eaton
President and CEO, i2 Pharmaceuticals

Prior to i2 Pharmaceuticals, Bruce Eaton was COO at SomaLogic. Before that he was the Chairman of the Department of Chemistry and Biochemistry at the University of Colorado Boulder. He has been engaged in commercial biotechnology since 1981. Dr. Eaton is named as either inventor or co-inventor on over 70 issued patents world-wide. He has served as consultant to a variety of biotechnology companies leading to successful product launches and two successful company IPO’s. From 2004-2005, he directed the research efforts at SomaLogic and served as a senior advisor to the company until 2011. Prior to that, Dr. Eaton was the President and Founder of Invenux, Inc., a tools-based drug discovery company. In 2000, he was also instrumental in founding Cropsolution, Inc.,  an agrichemical discovery company.  From 1995-1999, Dr. Eaton was the Vice President of Chemistry with global responsibility and directed the efforts of over 50 scientists at NeXstar Pharmaceuticals, including the group responsible for the production of the first successful aptamer IND, NX1838 now known as Macugen™ (Eyetech Pharmaceuticals), for age-related macular degeneration. 

April Giles
President and CEO, Colorado BioScience Association

April Giles joined the CBSA as Director of Operations in 2006 and was promoted to Vice President, Administration & Operations in 2009 followed by Executive Vice President in 2010. She became president and CEO of the organization in November 2012. Aprl, who previously worked in the Board of Regents office at the University of Colorado, has helped lead CBSA from a small startup enterprise to a statewide advocacy organization with more than 350 members. Most notably at CBSA, Giles led the strategic initiative to launch the first-ever Rocky Mountain Life Science Investor & Partnering Conference (RMLIPC) in 2009. The RMLIPC has driven the development of regional partnerships and now held biannually. April graduated with a Bachelor of Social Work degree from the University of Kansas and practiced in the profession for three years.

Todd Headley
President, CSU Ventures

Todd Headley has served as CSU Ventures President since 2011.  CSU Ventures  is dedicated to commercializing technology and innovations developed at Colorado State University.  Todd previously held roles in technology commercialization and business development at the University of Nebraska Medical Center, Iowa State University, and the University of Wisconsin-Madison. Prior to entering the university technology commercialization field, Todd spent 10 years working in the biopharmaceutical industry for Schering-Plough and Wyeth, primarily engaged in manufacturing and product development activities. He holds bachelor's degrees in both Microbiology and Environmental Science from South Dakota State University and an MBA from Iowa State University.  

Mark Lupa, Ph.D.
Managing Partner, High Country Ventures 

Mark Lupa has been Managing Partner of High Country Venture, which invests in early stage companies in the Life Science and IT industries, since 2004. From 1998 to 2005 he ws a Partner at Tango ventures. He was Founder, CEO, and CFO of Tabernash Brewing Company. He has 15 years of medical research experience, including post-doctoral fellowships at the University of Colrado (Neuroscience) and USCF Medical Center (Neuroscience).  He has a BSc in Bioengineering from Northwestern University, Masters in Bioengineering and PhD in Pharmacology. In addition to CID4, he serves on the boards of LeftHand/Tabernash, Oberon, TheraTogs, Surefire Medical, Endoshape, Mosaic Biosciences, Aktivax, and was a founding member of the the Taligen Board of Directors.

Kate Tallman
Associate Vice President for Technology Transfer, University of Colorado

Kate Tallman was appointed Interim Associate Vice President for Technology Transfer at the University of Colorado in July 2013; this role was made permanent in October 2014. As AVP she has responsibility for intellectual property and technology licensing matters across CU’s four campuses. Kate directed tech transfer operations for CU’s Boulder and Colorado Springs campuses since 2007, and was appointed a Senior Director in 2012. She joined CU Tech Transfer in 2002 as a member of the Boulder licensing group specializing in software licensing. Kate has served as an instructor in the Association of University Technology Managers software licensing course. Previously, Kate was a co-founder and Director of Marketing at Roving Planet, a venture-backed Colorado software company that developed wireless LAN technology. She earned her MBA from CU-Boulder’s Leeds College of Business, where she focused on marketing. She previously spent four years as a research analyst, performing market and financial analysis of health care companies.

Jonathan Thorne
Chief Executive Officer, Edgeport Surgical 

Jonathan Thorne is CEO of Edgeport Surgical, a medical product development and investment company based in Boulder. Prior to Edgeport, Mr. Thorne served as President and CEO of Silverglide Surgical Technologies, a medical device company specializing in neurosurgery products. Mr. Thorne founded Silverglide in 1997. Silverglide was capitalized completely with funds from friends, family and angels. Under Mr. Thorne’s leadership, Silverglide grew into a multi-million dollar medical device company. Silverglide attained profitability and successfully defended their intellectual property through litigation. In 2006, Mr. Thorne guided the company to acquisition by Stryker Corporation. Mr. Thorne started his career in the medical device industry in 1985 and has held management positions with Ohmeda Medical Systems and Battelle Memorial Institute. He received a BS degree in Mechanical Engineering from The University of Wyoming in 1983 and an MBA from The University of Denver in 1994. Mr. Thorne is a native of Colorado and resides with his family in Boulder.  

Steve VanNurden 
Chief Executive Officer, Fitzsimons Redevelopment Authority 

Steve VanNurden is President and CEO of the Fitzsimons Redevelopment Authority (FRA) in Aurora, Colorado. Prior to coming to the FRA, Mr. VanNurden was Chair of Mayo Clinic Ventures, the commercialization arm of Mayo Clinic in Rochester, Minnesota. During Mr. VanNurden’s tenure, Mayo Clinic Ventures commercialized nearly 2,000 Mayo Clinic discoveries, inventions and other Intellectual Property primarily through conventional licensing agreements. In 1998, the Technology Based Ventures (TBV) program was added to Mayo Clinic Ventures, which allows Mayo to evaluate internal technologies for possible formation of new start-up companies. The program has resulted in the formation of over 45 companies since inception. Previous to becoming Chair of Mayo Clinic Ventures, Mr. VanNurden held a variety of positions in the other operating divisions during his 22 years at Mayo Clinic, including being the first Director of Electronic Publishing in the Health Information Division. He also served as an industry liaison to the U.S. Health and Human Services Committee on the Emergence of Interactive Health Communication. Previously, Mr. VanNurden held management positions at Cargill, Inc., US Bank and was vice-president of Aerodrome Airline Services, Inc., a small aviation company. Mr. VanNurden holds degrees in Accounting and Finance and a Masters Degree in Business Administration.